UPCOMING THEMATIC ISSUE – DRUG DISCOVERY AND DEVELOPMENT IN THE MANAGEMENT OF CARDIOMETABOLIC DISEASES – CURRENT DRUG TARGETS

CDT-THEMATIC FLYER-Jun Ren, MD, PhD

https://benthamscience.com/journals/current-drug-targets/

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Current Pharmaceutical Design 23-45

http://bit.ly/2oIv7mL

Current Pharmaceutical Design 23-46

http://bit.ly/2D0nCMq

Current Medical Imaging Reviews 14-2

http://bit.ly/2I2VBrq

Current Drug Targets 19-4

http://bit.ly/2FfOgmC

Current Cancer Drug Targets 18-3

http://bit.ly/2teYjqv

recent-issues

WISHING A VERY HAPPY BIRTHDAY TO PROF. FRANCIS J. CASTELLINO!

Prof. Francis J. Castellino.jpg

PROF. FRANCIS J. CASTELLINO

JOURNAL: CURRENT DRUG TARGETS

KLEIDERER-PEZOLD PROFESSOR OF BIOCHEMISTRY,
DIRECTOR, W.M. KECK CENTER FOR TRANSGENE RESEARCH,
DEAN EMERITUS, COLLEGE OF SCIENCE,
230 RACLIN-CARMICHAEL HALL, UNIVERSITY OF NOTRE DAME,
NOTRE DAME, IN 46556,
USA

UPCOMING THEMATIC ISSUE – THE COMPUTATIONAL METHODS IN DRUG TARGETS DISCOVERY – CURRENT DRUG TARGETS

CDT-THEMATIC FLYER-Hao Lin Ph.D. & Prof

https://benthamscience.com/journals/current-drug-targets/special-issues/

New Issue :: Current Drug Targets Volume 19, Issue 2

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

cdt

Articles from the journal Current Drug Targets Volume 19, Issue 2:

                          For details on the articles, please visit this link :: http://bit.ly/2noTuWi

 

 

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Current Psychiatry Reviews13-3

http://bit.ly/2BsgWHK

Anti-Cancer Agents in Medicinal Chemistry 17-11

http://bit.ly/2B9JYyY

Current Medicinal Chemistry 24 -36

http://bit.ly/2CWxoR8

Current Organic Chemistry 21-23

http://bit.ly/2oAC1Nr

Current Organic Synthesis 14 -7

http://bit.ly/2CTfgr8

Current Pharmaceutical Design 23-30

http://bit.ly/2oAUXvo

Current Drug Targets  18-16

http://bit.ly/2jbzp3c

Current Medicinal Chemistry 24 -37

http://bit.ly/2CUDmSr

Current Genomics 19 -1

http://bit.ly/2BaL5hR

Current Pharmaceutical Design 23 -31

http://bit.ly/2ARCYm4

recent-issues

EDITOR’S CHOICE – Cell Wall Associated Factors of Mycobacterium tuberculosis as Major Virulence Determinants – Current Drug Targets

Journal: Current Drug Targets

Author(s): Gurdyal Singh, Arbind Kumar, Pratibha Maan, Jagdeep Kaur

Graphical Abstract:

Abstract:

Background: Mycobacteria genus is responsible for deadly diseases like tuberculosis and leprosy. Cell wall of bacteria belonging to this genus is unique in many ways. It plays a major role in the pathogenesis and intracellular survival inside the host. In intracellular pathogens, their cell wall acts as molecular shield and interacts with host cell milieu to modulate host defense responses.

Objectives: In this review, we summarize the factors that participate in the biosynthesis of unique mycobacterial cell wall, understand their potential as drug targets and the recent developments where they have been evaluated as possible drug targets.

Results: Several cell wall associated factors that play crucial roles in the synthesis of cell wall components like Antigen 85 complex, Glycosyltransferases (GTs), LM (lipomannan) and LAM (lipoarabinomannan), mAGP Complex, lipolytic enzyme have been categorically documented. Most of the presently used anti TB regimens interrupted cell wall synthesis, but the emergence of drug resistant strains made it mandatory to identify new drug targets. Novel drug candidates which could inhibit the synthesis of cell wall components have been thoroughly studied worldwide.

Conclusion: Studies demonstrated that the cell wall components are unique in terms of their contribution in mycobacterium pathogenesis. Targeting these can hamper the growth of M. tuberculosis. In this study, we scrutinize the drugs under trials and the potential candidates screened through in silico findings.

 

To access the article, please visit: http://www.eurekaselect.com/154134

HIGHLIGHTED ARTICLE – THE BLOOD BRAIN BARRIER AND ITS ROLE IN ALZHEIMER’S THERAPY – CURRENT DRUG TARGETS

cdt-Articles_18- 16-Satya Lavanya - Copy.jpg

https://benthamscience.com/journals/current-drug-targets/special-issues/#top

New Issue :: Current Drug Targets 18, Issue 13

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

cdt

 

Articles from the journal Current Drug Targets, Volume 18, Issue 13:

For details on the articles, please visit this link :: http://bit.ly/2hJRdlp

 

 

 

 

Press Release for EurekAlert! The role of electrochemotherapy in radiosensitization of tumor cells

This article by Dr. Ali Yadollahpour et al. is published in Current Drug Targets, Volume 18, 2017

 

Radiotherapy is an important method in treatment of tumors, but it can be held responsible for biological damages. Improvements in this therapeutic method have begun by developing targeted drug delivery system along with developing efficient radiosensitizing agents through which targeted uptake of the chemotherapeutic drugs into the tumor cells and tumor specific sensitization are increased. Electroporation (EP) has shown promising potentials as a targeted drug delivery system and radiosensitizing technique. EP increases chemotherapy drug uptake in the tumor cells which in turn increases its intracellular accumulation and thus the radiosensitizing effect. When EP is combined by chemotherapeutic drugs, this treatment is named ECT.

There are two basic requirements for an effective ECT: (1) appropriate electrical parameters and (2) type, administration route, and concentration of chemotherapeutic agent. In all studies (preclinical & clinical), the best treatment response was obtained in the group that treated with ECT before irradiation. In addition, previous studies showed that the skin tumors of the head and neck can be successfully treated with a combination of ECT and electron beam in clinics. We can conclude that combination of ECT and radiotherapy can be considered for patients with progressive skin tumors in the head and neck area to increase the likelihood of a favorable therapeutic outcome and to preserve cosmetic appearance and function of the normal surrounding tissues.

In summary, three main mechanisms have been reportedly responsible for radiosensitizing effect of ECT: (1) increased drug uptake in the cells due to EP phenomenon, (2) generation of reactive oxygen species by electric pulses, and (3) vascular alteration particularly antivascular effects.

For further information about this research, please visit: http://www.eurekaselect.com/153527

%d bloggers like this: